InsidersTradesSigma
Total declarations
Companies
▲ Purchases (19 ops.)
▼ Sales (1 ops.)
Insider track record
OtherDisclosed buys
19
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Clifton R. LaDuane. Director active across 2 companies, notably Kempharm, INC. Cumulatively, 21 reports have been published. Split: 19 buys · 1 sell. Total volume traded: €152k. Activity tracked since 27 May 2021. The latest transaction was disclosed on 13 February 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations21 total
11,000 shares@ US$7.86177.6% of flowCommon StockSEC:0001437749-25-004068:0
43,333 sharesCommon StockSEC:0001437749-25-002625:0
2,000 shares@ US$6.7711.5% of flowCommon StockSEC:0001437749-24-022939:0
Ideal exit: 13 Apr 2025 (T+270)
1,000 shares@ US$4.95914.3% of flowCommon StockSEC:0001437749-23-025317:0
Ideal exit: 2 Jun 2024 (T+270)
51 shares@ US$4.940.2% of flowCommon StockSEC:0001437749-23-015140:0
Ideal exit: 12 Feb 2024 (T+270)
1,725 shares@ US$4.156.3% of flowCommon StockSEC:0001437749-23-006277:0
Ideal exit: 5 Dec 2023 (T+270)
610 shares@ US$5.827.3% of flowCommon StockSEC:0001437749-23-001060:0
Ideal exit: 10 Oct 2023 (T+270)
600 shares@ US$5.988.1% of flowCommon StockSEC:0001437749-22-023512:0
Ideal exit: 27 Jun 2023 (T+270)
1,200 shares@ US$4.999215.0% of flowCommon StockSEC:0001437749-22-012932:0
Ideal exit: 12 Feb 2023 (T+270)
510 shares@ US$8.298.3% of flowCommon StockSEC:0001437749-21-027098
Ideal exit: 15 Aug 2022 (T+270)
510 shares@ US$8.299.8% of flowCommon StockSEC:0001437749-21-027098:0
Ideal exit: 15 Aug 2022 (T+270)
215 shares@ US$9.384.6% of flowCommon StockSEC:0001437749-21-022841:0
Ideal exit: 26 Jun 2022 (T+270)
215 shares@ US$9.383.9% of flowCommon StockSEC:0001437749-21-022841
Ideal exit: 26 Jun 2022 (T+270)
935 shares@ US$8.586518.0% of flowCommon StockSEC:0001437749-21-022431:0
Ideal exit: 17 Jun 2022 (T+270)
935 shares@ US$8.586515.2% of flowCommon StockSEC:0001437749-21-022431
Ideal exit: 17 Jun 2022 (T+270)
230 shares@ US$9.1054.6% of flowCommon StockSEC:0001437749-21-021308:0
Ideal exit: 29 May 2022 (T+270)
230 shares@ US$9.1053.9% of flowCommon StockSEC:0001437749-21-021308
Ideal exit: 29 May 2022 (T+270)
75 shares@ US$14.112.0% of flowCommon StockSEC:0001437749-21-015562
Ideal exit: 20 Mar 2022 (T+270)
75 shares@ US$14.112.3% of flowCommon StockSEC:0001437749-21-015562:0
Ideal exit: 20 Mar 2022 (T+270)
150 shares@ US$9.853.2% of flowCommon StockSEC:0001437749-21-013577:0
Ideal exit: 21 Feb 2022 (T+270)
150 shares@ US$9.853.2% of flowCommon StockSEC:0001437749-21-013577
Ideal exit: 21 Feb 2022 (T+270)
21 of 21 declarations
About Clifton R. LaDuane
Clifton R. LaDuane is a director at Kempharm, INC.
